FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Cytokine topics
Antibodies
Inflammation
Specificity
Immunotherapy
Major Histocompatibility Complex
Compatibility
Combination Therapy
Histocompatibility
Immune Response
Monoclonal Antibody
Stimulator
Therapeutics
Immunostimulator
Monoclonal
Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cytokine patents



      
           
This page is updated frequently with new Cytokine-related patent applications. Subscribe to the Cytokine RSS feed to automatically get the update: related Cytokine RSS feeds. RSS updates for this page: Cytokine RSS RSS


Date/App# patent app List of recent Cytokine-related patents
12/11/14
20140363529
 Compounds influencing fatty acid uptake and metabolism and methods of isolating from cocoa products patent thumbnailCompounds influencing fatty acid uptake and metabolism and methods of isolating from cocoa products
The invention provides compounds and plant extract compositions that inhibit pancreatic enzymes, such as lipases and amylases, and most particularly pancreatic lipase and phospholipase a2 (pla2), and cox-2 enzyme, and improve the inflammatory state or response conditions in animals. The compounds and plant extracts can be used in methods and administration regimens to treat animals for obesity-related conditions, diabetes and related conditions, metabolic syndrome, metabolic endotoxemia, and inflammatory conditions.
12/11/14
20140363500
 Use of an antibody and a particulate immunomodulator patent thumbnailUse of an antibody and a particulate immunomodulator
The current invention is directed to particulate or vesicular immunomodulators, like e.g. Cytokines, for use in combination therapy with antibodies for treatments of a range of conditions and diseases, in particular cancer, as well as methods, compositions, and kits thereof..
12/11/14
20140363499
 Use of a particulate immunomodulator in cancer therapy patent thumbnailUse of a particulate immunomodulator in cancer therapy
The current invention is directed to a particulate or vesicular formulation of an immune modulating molecule, like e.g. Cytokines, as well as uses, methods, compounds thereof.
12/11/14
20140363456
 Tumor-specific gm-csf cytokine response as predictor of cancer vaccine effectiveness patent thumbnailTumor-specific gm-csf cytokine response as predictor of cancer vaccine effectiveness
The present invention relates to methods of treating cancer with a cancer vaccine using granulocyte-macrophage colony-stimulating factor (gm-csf) as a biomarker; methods of prognosticating an outcome of cancer treatment with a cancer vaccine using gm-csf as a biomarker; methods for qualifying subjects for cancer vaccination using gm-csf as a biomarker; methods for comparing the efficacy of two or more cancer vaccine treatments based on gm-csf response; and kits for the effective treatment of cancer.. .
12/04/14
20140357936
 Non-invasive treatment of neurodegenerative diseases patent thumbnailNon-invasive treatment of neurodegenerative diseases
Methods and devices are disclosed for the non-invasive treatment of neurodegenerative diseases through delivery of energy to target nervous tissue, particularly the vagus nerve. The devices include a magnetic stimulator having coils with toroidal windings, which are in contact with an electrically conducting medium that is adapted to conform to the contour of a target body surface of a patient.
12/04/14
20140356373
 Methods and compositions for treating lupus patent thumbnailMethods and compositions for treating lupus
The invention relates to compositions and methods for treating lupus. The methods typically comprise the step of administrating one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, meisoindigo and natura in an amount sufficient to treat the lupus; preferably by modulating cytokine expression.
11/27/14
20140350527
 "self-regulating device for modulating inflammation"
A bioreactor is provided which contains cells capable of producing cytokine inhibitors in response to cytokines, in a manner regulated by the local or systemic milieu of an individual patient and predicted by mechanistic computational simulations. The bioreactor transfers the cytokine inhibitors to a patient in need of control of the inflammation process as part of a disease or condition in the patient, such as sepsis, trauma, traumatic brain injury, or wound healing.
11/27/14
20140350250
 Therapeutic agent for cerebral infarction patent thumbnailTherapeutic agent for cerebral infarction
The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient. The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having an effect of suppressing brain injury volume or improving neurological deficit, since it suppresses production of plural inflammatory cytokines and chemokines present in the brain such as tnf-α, il-1β, il-6 and mcp-1 and the like..
11/27/14
20140350249
 Therapeutic agent for cerebral infarction patent thumbnailTherapeutic agent for cerebral infarction
The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient. The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having an effect of suppressing brain injury volume or improving neurological deficit, since it suppresses production of plural inflammatory cytokines and chemokines present in the brain such as tnf-α, il-1β, il-6 and mcp-1 and the like..
11/27/14
20140348940
 Amniotic membrane hydrogel and methods of making patent thumbnailAmniotic membrane hydrogel and methods of making
The present invention provides compositions and methods for wound healing and tissue regeneration. The compositions of the present invention comprise amniotic membrane of the placenta.
11/27/14
20140348789
Targeted mutant alpha-helical bundle cytokines
This disclosure relates to a modified α-helical bundle cytokine, with reduced activity via an α-helical bundle cytokine receptor, wherein the α-helical bundle cytokine is specifically delivered to target cells. Preferably, the α-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells.
11/27/14
20140348783
Vaccine immunotherapy for immune suppressed patients
A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive t-cells and restoring t-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive t-cells and exposing the naive t-cells to endogenous or exogenous antigens at an appropriate site.
11/27/14
20140348782
Vaccine immunotherapy for immune suppressed patients
A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive t-cells and restoring t-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive t-cells and exposing the naive t-cells to endogenous or exogenous antigens at an appropriate site.
11/20/14
20140343059
Novel piperazines, pharmaceutical compositions and methods of use thereof
Disclosed are novel piperazine derivatives that act as agonists of the α7 nachr. Also disclosed are pharmaceutical compositions, methods of treating inflammatory conditions, methods of treating cns disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds..
11/20/14
20140342936
Methods and kits for diagnosing latent tuberculosis infection
The present invention relates to a method for diagnosing latent tuberculosis infection in a subject comprising the step i) consisting of incubating a biological sample obtained from the subject with at least one mycobacterium tuberculosis antigen, and thereafter a step ii) consisting of quantifying in said biological sample the secretion of at least one cytokine selected from the group consisting of il-2, il-15, ip-10 and mig.. .
11/20/14
20140342468
Single molecule assays
The present invention provides single molecule analyses of species of use in analytical, diagnostic or prognostic assays. In exemplary embodiments, the assays utilize samples prepared by novel methods, affording assays of unexpected sensitivity and robustness.
11/20/14
20140342015
Amniotic membrane powder and methods of making
The present invention provides compositions and methods for wound healing and tissue regeneration. The compositions of the present invention comprise amniotic membrane of the placenta.
11/20/14
20140341880
Risk predictors for adverse perinatal outcomes
Methods for assessing a risk of experiencing an adverse perinatal outcome in a subject are described. The methods include determining a level of at least one cytokine in a biological sample from the subject; and comparing the level of the at least one cytokine in the subject's biological sample with a predetermined value based on levels of the at least one cytokine in a biological sample from a population of control subjects, wherein a subject whose level of at least one cytokine is greater than the predetermined line value is at risk of experiencing an adverse perinatal outcome..
11/20/14
20140341844
Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer
This invention relates to the treatment of cancer using anti-erbb antibodies, such as cetuximab or trastuzumab, in combination with antibody-interleukin 2 (il2) conjugates which target tenascin-c.. .
11/20/14
20140341843
Purified proteins
The present invention provides methods and compositions for the preparation and delivery of chimeric cytokine proteins, including cell cultures, methods of purification and purified compositions.. .
11/13/14
20140336220
Composition for preventing or treating obesity comprising rebamipide
The present disclosure relates to a composition and a health functional food for preventing or treating obesity comprising a rebamipide compound or its pharmaceutically acceptable salt as an active component. It is confirmed that when a rebamipide compound of the present disclosure is administered to a mouse model induced with obesity, it shows excellent effects of reducing weight, reducing adipocyte, and reducing a total cholesterol content in the body, as compared with a non-administered control group, and also, it shows an excellent effect of suppressing differentiation of cytotoxic th17 cells that generate and secrets inflammatory cytokine and an excellent effect of improving activity of regulatory t cells (treg) capable of suppressing a function of abnormally activated immune cells and controlling an inflammatory reaction.
11/13/14
20140336076
Method for diagnosing and treating fibromyalgia
The invention provides methods, kits and reagents for diagnosing fibromyalgia (fm) in an individual by determining whether the levels of one or more cytokines in the individual are altered, as compared to control levels. The altered level(s) or patterns of expression of the cytokines measured in the affected individual compared to the level from the control is predictive/indicative of fm in the.
11/13/14
20140335108
Utility of insulin-like 6 (insl6) for the treatment of autoimmune diseases
The present invention is directed to compositions and methods to treat an autoimmune disease in a subject, comprising an insulin-like 6 (insl6) agent, such as an insl6 polypeptide or variant or fragment thereof, or a nucleic acid encoding insl6 poly peptide or variant or fragment thereof. Aspects of the present invention relate to use of insl6 agents to reduce t-regulatory (treg) cells in the subject and to reduce pro-inflammatory cytokines in a subject with an autoimmune disease such as a muscle autoimmune disease.
11/13/14
20140335103
Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells..
11/13/14
20140335094
Mammalian cytokines; related reagents and methods
Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided..
11/06/14
20140330349
Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
Described herein are systems and methods for applying extremely low duty-cycle stimulation sufficient to treat chronic inflammation with progressively longer delays (off periods) from an initial stimulation. In particular, described herein are supra-threshold pulses of electrical stimulation sufficient to result in a long-lasting (e.g., >48 hours) inhibition of pro-inflammatory cytokines and/or effects of chronic inflammation; the delay between initial doses (which may be single-pulse doses) may be extended for subsequent doses, potentially dramatically enhancing battery and device longevity..
11/06/14
20140329721
Assay panels
Described herein are kits and components thereof used for a multiplexed analysis of a set of cytokines.. .
11/06/14
20140328798
Co-administration of a parvovirus and a cytokine for therapy of pancreatic cancer
The present invention relates to a combination of a parvovirus and a cytokine, preferably ifnγ, for use in treating pancreatic cancer, in particular a terminal stage of this disease.. .
10/30/14
20140323731
Lipidated imidazoquinoline derivatives
The compounds of the subject invention are adjuvant molecules that comprise an imidazoquinoline molecule covalently linked to a phospho- or phosphonolipid group. The compounds of the invention have been shown to be inducers of interferon-a, il-12 and other immunostimulatory cytokines and possess an improved activity profile in comparison to known cytokine inducers when used as adjuvants for vaccine antigens..
10/30/14
20140323401
Tissue protective peptides and uses thereof
The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex.
10/30/14
20140323355
Urinary biomarkers for cancer diagnosis
The present invention is directed to the field of cancer diagnosis, specifically to the diagnosis of bladder cancer (bc) and prostate cancer (cap). More specifically, the invention provides simple, non-invasive urinary tests characterized by high sensitivity and specificity, wherein urinary levels of heat shock proteins and anti-inflammatory cytokines are used as biomarkers..
10/30/14
20140322266
Induction of mucosal tolerance to antigens
The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of foxp3+ and/or il-10 and/or tgf-β producing regulatory t-cells, capable of suppressing undesired immune responses toward an antigen, by oral delivery of said antigen in combination with an immunosuppressing cytokine secreting micro-organism..
10/30/14
20140322249
Dna vaccines against tumor growth and methods of use thereof
A dna vaccine suitable for eliciting an immune response against cancer cells comprises a dna construct operably encoding a cancer-associated inhibitor of apoptosis-family protein and an immunoactive gene product, such as a cytokine or a ligand for a natural killer cell surface receptor, in a pharmaceutically acceptable carrier. A preferred cytokine is ccl21.
10/30/14
20140322230
Induction of mucosal tolerance to antigens
The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of foxp3+ and/or il-10 and/or tgf-β producing regulatory t-cells, capable of suppressing undesired immune responses toward an antigen, by oral delivery of said antigen in combination with an immunosuppressing cytokine secreting micro-organism..
10/23/14
20140316109
Activated collagen scaffold materials and their special fused active restoration factors
Provided are activated collagen scaffold materials as well as their special fused active restoration factors useful for promoting tissue repair, such as bone damage repair or nerve injury repair. The special fused active restoration factors are fusion proteins comprising a collagen-binding domain (cbd) at n-/c-terminus of cytokines, wherein the collagen-binding domain is a polypeptide consisting of 7-27 amino acid residues with a conservative sequence shown in seq id no:12 at n-terminus.
10/23/14
20140315253
Activated collagen scaffold materials and their special fused active restoration factors
Provided are activated collagen scaffold materials as well as their special fused active restoration factors useful for promoting tissue repair, such as bone damage repair or nerve injury repair. The special fused active restoration factors are fusion proteins comprising a collagen-binding domain (cbd) at n-/c-terminus of cytokines, wherein the collagen-binding domain is a polypeptide consisting of 7-27 amino acid residues with a conservative sequence shown in seq id no:4 at n-terminus.
10/23/14
20140314872
Methods of use of culture supernatant obtained from mesenchymal stem cells from dogs and cats for treatment of organ dysfunction
A method of treatment of organ dysfunction using a supernatant containing molecules, cytokines and vesicles secreted from mesenchymal stem cells (msc) from animals is provided. The msc are cultured, and then centrifuged to separate them from the desired supernatant containing the molecules and vesicles that may be used for treatment.
10/23/14
20140314710
Il-12 p40 monomer, monoclonal antibody against p40 homodimer and the combination of the two for autoimmune disease treatment
A novel approach to discover new drugs against ms and other autoimmune diseases is disclosed. The p40 family of cytokines has four members which include interleukin-12 (il-12), the p40 monomer (p40), the p40 homodimer (p402), and the il-23.
10/23/14
20140311482
Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
The disclosure describes an aerosolizer with (i) means sized for intranasal or paranasal insertion that produces an aerosol from a material for delivery in close proximity to the upper airways, and (ii) the material comprising one or more proinflammatory cytokine inhibitor(s).. .
10/16/14
20140308747
Ex vivo expansion of human hematopoietic stem cells
Methods and kits for expanding the number of hematopoietic stem cells are provided. The methods comprise incubating cells in medium comprising isolated igfbp-2 and an angiopoietin-like protein (angptl).
10/16/14
20140308244
Combination therapy for treatment of inflammatory demyelinating disease
Provided herein include combination therapies for the treatment of neurological inflammatory diseases, such as, for example, demyelinating autoimmune diseases, such as multiple sclerosis and neuromyelitis optica, etc. In various aspects and embodiments, the methods may include administering to a patient an effective dose of an inhibitor of an angiotensin-converting enzyme (ace) in combination with one or more second compounds, in one aspect, provided is a method of treating a demyelinating autoimmune disease (such as multiple sclerosis) that includes administering to a patient an effective dose of an inhibitor of an angiotensin-converting enzyme (ace) in combination with one or more compounds selected from the group consisting of a cytokine, a vitamin b, dimethyl fumarate (dmf, also referred to as bg-12) and fingolimod (gilenya)..
10/16/14
20140308239
Chimeric cytokine formulations for ocular delivery
Featured herein are vehicle formulations and formulations containing a chimeric cytokine designed for e.g., ocular delivery.. .
10/09/14
20140302070
Novel pd1 isoforms, and uses thereof for potentiating immune responses
In one embodiment, the present invention provides a new isoform of human pd1 (Δ42pd1) that contains a 42-nucleotide in-frame deletion located at exon 2 domain. Δ42pd1 does not engage pd-l1/pd-l2, and can induce the production of pro-inflammatory cytokines in one embodiment, Δ42pd1 can be used as an intramolecular adjuvant to develop a fusion dna vaccine for enhancing antigen-specific cd8+ t cell immunity and for prevention of pathogenic infection and/or cancer.
10/09/14
20140301985
Method of treating pancreatic and liver conditions by endoscopic-mediated (or laparoscopic-mediated) transplantation of stem cells into/onto bile duct walls of particular regions of the biliary tree
A method of repairing diseased or dysfunctional pancreas or liver is provided. The method involves preparation of a suspension of stem cells and/or progenitor cells such as biliary tree stem cells, hepatic stem cells, pancreatic stem cells or their descendants, committed progenitor cells, from healthy tissue of the patient or of the biliary tree of a non-autologous donor and engrafting the cells into the wall of bile ducts near to the organ to be treated.


Popular terms: [SEARCH]

Cytokine topics: Antibodies, Inflammation, Specificity, Immunotherapy, Major Histocompatibility Complex, Compatibility, Combination Therapy, Histocompatibility, Immune Response, Monoclonal Antibody, Stimulator, Therapeutics, Immunostimulator, Monoclonal, Proinflammatory

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cytokine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cytokine with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         



Key IP Translations - Patent Translations



0.2085

3162

1 - 1 - 71